Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ancient Pompeii construction site reveals the process for creating Roman concrete - 2Israel and Lebanon's Hezbollah continue to trade attacks
- 3Change Your Skincare: 10 Inventive Magnificence Gadgets
- 4California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- 5IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- Surprising links between autism, Alzheimer’s could change how we treat both
- Coca-Cola Co. and bottlers to invest in South Africa operations
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- The 10 Most Famous Works of art Ever
- How Deforestation Is Reshaping Mosquito-Human Contact
- How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- Amateur's Manual for Venture Strategies for Tenderfoots
- When is MLK Day? Plus, the dates of when other federal holidays land in 2026.
